Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medical Imaging
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 1573-4056
  • E-ISSN: 1875-6603
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

68Ga-labeled prostate-specific membrane antigen positron emission tomography-computed tomography (68Ga-PSMA PET/CT) has led to altered treatment plans for prostate cancer (PCa) patients.

Objective

This study aimed to investigate the impact of 68Ga-PSMA PET/CT on overall survival (OS) and management in PCa.

Methods

Consecutive 100 patients who had 68Ga-PSMA PET/CT and conventional imaging (CI) were included in this retrospective study. Disease stages and treatment plans according to both CI and 68Ga-PSMA PET/CT were compared. The effect of 68Ga-PSMA PET/CT on OS was assessed.

Results

After 68Ga-PSMA PET/CT, the stage changed in 64 patients (64%). By the reason of 68Ga-PSMA PET/CT findings, treatment plans based on CI were changed in 73 patients (73%). According to the ROC analysis, patients with a PSA value below 8 had higher rates of change in staging (p<0.0001) and treatment (p=0.034). Both a PSA below 8 (OR 8.79 95% CI (2.72-28.43), p<0.001), and having a hormone-sensitive disease at the time of imaging (OR 5.6 95% CI (1.35-23.08), p=0.017) were significant independent factors predicting change in staging with 68Ga-PSMA PET/CT. The results of a phi correlation coefficient analysis showed a significant relationship between therapy and changes in staging (ϕ=0.638, p<0.0001). Two-year OS was statistically different in hormone-sensitive patients with and without treatment change (95% vs 81%, p=0.006).

Conclusion

68Ga-PSMA PET/CT has the effect of changing the treatment in 73% of PCa patients. There is a positive correlation between the changes in staging and treatment. Survival of hormone sensitive patients has improved due to treatment changes based on PET/CT findings.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056276494231207101146
2024-01-01
2025-06-22

  • From This Site

    /content/journals/cmir/10.2174/0115734056276494231207101146
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  2. de RooijM. HamoenE.H.J. WitjesJ.A. BarentszJ.O. RoversM.M. Accuracy of magnetic resonance imaging for local staging of prostate cancer: A diagnostic meta-analysis.Eur. Urol.201670223324510.1016/j.eururo.2015.07.02926215604
     [Google Scholar]
  3. HövelsA.M. HeesakkersR.A.M. AdangE.M. JagerG.J. StrumS. HoogeveenY.L. SeverensJ.L. BarentszJ.O. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis.Clin. Radiol.200863438739510.1016/j.crad.2007.05.02218325358
     [Google Scholar]
  4. Even-SapirE. MetserU. MishaniE. LievshitzG. LermanH. LeibovitchI. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.J. Nucl. Med.200647228729716455635
     [Google Scholar]
  5. HofmanM.S. LawrentschukN. FrancisR.J. proPSMA study group collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study.Lancet2020395102311208121610.1016/S0140‑6736(20)30314‑732209449
     [Google Scholar]
  6. DadgarH. EmamiF. NorouzbeigiN. VafaeeM.S. JafariE. GholamrezanezhadA. AssadiM. AhmadzadehfarH. Application of [68Ga]PSMA PET/CT in diagnosis and management of prostate cancer patients.Mol. Imaging Biol.20202241062106910.1007/s11307‑019‑01445‑z31758511
     [Google Scholar]
  7. ZachoH.D. NielsenJ.B. HaberkornU. StenholtL. PetersenL.J. 68 Ga- PSMA PET / CT for the detection of bone metastases in prostate cancer: A systematic review of the published literature.Clin. Physiol. Funct. Imaging201838691192210.1111/cpf.12480
     [Google Scholar]
  8. Afshar-OromiehA. HaberkornU. HadaschikB. HablG. EderM. EisenhutM. SchlemmerH.P. RoethkeM.C. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer.Eur. J. Nucl. Med. Mol. Imaging201340101629163010.1007/s00259‑013‑2489‑523817686
     [Google Scholar]
  9. Afshar-OromiehA. AvtziE. GieselF.L. Holland-LetzT. LinhartH.G. EderM. EisenhutM. BoxlerS. HadaschikB.A. KratochwilC. WeichertW. KopkaK. DebusJ. HaberkornU. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.Eur. J. Nucl. Med. Mol. Imaging201542219720910.1007/s00259‑014‑2949‑625411132
     [Google Scholar]
  10. EiberM. MaurerT. SouvatzoglouM. BeerA.J. RuffaniA. HallerB. GranerF.P. KüblerH. HaberhornU. EisenhutM. WesterH.J. GschwendJ.E. SchwaigerM. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy.J. Nucl. Med.201556566867410.2967/jnumed.115.15415325791990
     [Google Scholar]
  11. Sanchez-CrespoA. JussingE. BjörklundA.C. Pokrovskaja TammK. Hallmarks in prostate cancer imaging with Ga68-PSMA-11-PET/CT with reference to detection limits and quantitative properties.EJNMMI Res.2018812710.1186/s13550‑018‑0378‑429619657
     [Google Scholar]
  12. SterzingF. KratochwilC. FiedlerH. KatayamaS. HablG. KopkaK. Afshar-OromiehA. DebusJ. HaberkornU. GieselF.L. 68Ga-PSMA-11 PET/CT: A new technique with high potential for the radiotherapeutic management of prostate cancer patients.Eur. J. Nucl. Med. Mol. Imaging2016431344110.1007/s00259‑015‑3188‑126404016
     [Google Scholar]
  13. HrubyG. EadeT. EmmettL. HoB. HsiaoE. SchembriG. GuoL. KwongC. HunterJ. ByrneK. KneeboneA. 68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.Asia Pac. J. Clin. Oncol.201814434334610.1111/ajco.1287229663686
     [Google Scholar]
  14. EkmekciogluÖ. BusstraM. KlassN.D. VerzijlbergenF. Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence—a narrative review of the literature.J. Nucl. Med.201960101394139810.2967/jnumed.118.22288530850500
     [Google Scholar]
  15. EderM. NeelsO. MüllerM. Bauder-WüstU. RemdeY. SchäferM. HennrichU. EisenhutM. Afshar-OromiehA. HaberkornU. KopkaK. Novel preclinical and radiopharmaceutical aspects of [68Ga] Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer.Pharmaceuticals20147777979610.3390/ph707077924983957
     [Google Scholar]
  16. EderM. SchäferM. Bauder-WüstU. HullW.E. WänglerC. MierW. HaberkornU. EisenhutM. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.Bioconjug. Chem.201223468869710.1021/bc200279b22369515
     [Google Scholar]
  17. SchäferM. Bauder-WüstU. LeottaK. ZollerF. MierW. HaberkornU. EisenhutM. EderM. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.EJNMMI Res.2012212310.1186/2191‑219X‑2‑2322673157
     [Google Scholar]
  18. SchwarzenboeckS.M. RauscherI. BluemelC. FendlerW.P. RoweS.P. PomperM.G. Asfhar-OromiehA. HerrmannK. EiberM. PSMA ligands for PET imaging of prostate cancer.J. Nucl. Med.201758101545155210.2967/jnumed.117.19103128687599
     [Google Scholar]
  19. FendlerW.P. CalaisJ. Allen-AuerbachM. BluemelC. EberhardtN. EmmettL. GuptaP. HartenbachM. HopeT.A. OkamotoS. PfobC.H. PöppelT.D. RischplerC. SchwarzenböckS. StebnerV. UnterrainerM. ZachoH.D. MaurerT. GratzkeC. CrispinA. CzerninJ. HerrmannK. EiberM. 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study.J. Nucl. Med.201758101617162310.2967/jnumed.117.19082728408531
     [Google Scholar]
  20. Witkowska-PatenaE. GiżewskaA. DziukM. MiśkoJ. BudzyńskaA. Walęcka-MazurA. Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml.Prostate Cancer Prostatic Dis.202023234334810.1038/s41391‑019‑0194‑631780781
     [Google Scholar]
  21. CalaisJ. FendlerW.P. EiberM. GartmannJ. ChuF.I. NickolsN.G. ReiterR.E. RettigM.B. MarksL.S. AhleringT.E. HuynhL.M. SlavikR. GuptaP. QuonA. Allen-AuerbachM.S. CzerninJ. HerrmannK. Impact of 68 Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence.J. Nucl. Med.201859343444110.2967/jnumed.117.20294529242398
     [Google Scholar]
  22. CytawaW. SeitzA.K. KircherS. FukushimaK. Tran-GiaJ. SchirbelA. BandurskiT. LassP. KrebsM. PołomW. MatuszewskiM. WesterH.J. BuckA.K. KüblerH. LapaC. 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.Eur. J. Nucl. Med. Mol. Imaging202047116817710.1007/s00259‑019‑04524‑z31529265
     [Google Scholar]
  23. BluemelC. KrebsM. PolatB. LinkeF. EiberM. SamnickS. LapaC. LassmannM. RiedmillerH. CzerninJ. RubelloD. BleyT. KropfS. WesterH.J. BuckA.K. HerrmannK. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT.Clin. Nucl. Med.201641751552110.1097/RLU.000000000000119726975008
     [Google Scholar]
  24. FerraroD.A. Garcia SchülerH.I. MuehlematterU.J. EberliD. MüllerJ. MüllerA. GablingerR. KranzbühlerH. OmlinA. KaufmannP.A. HermannsT. BurgerI.A. Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer.Eur. J. Nucl. Med. Mol. Imaging202047365266410.1007/s00259‑019‑04568‑131802175
     [Google Scholar]
  25. RoachP.J. FrancisR. EmmettL. HsiaoE. KneeboneA. HrubyG. EadeT. NguyenQ.A. ThompsonB.D. CusickT. McCarthyM. TangC. HoB. StrickerP.D. ScottA.M. The impact of (68) Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study.J. Nucl. Med.2018591828810.2967/jnumed.117.19716028646014
     [Google Scholar]
  26. AlbisinniS. ArtigasC. AounF. BiaouI. GrosmanJ. GilT. HawauxE. LimaniK. OtteF.X. PeltierA. SiderisS. SirtaineN. FlamenP. van VelthovenR. Clinical impact of 68 Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate‐specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.BJU Int.2017120219720310.1111/bju.1373927981732
     [Google Scholar]
  27. DewesS. SchillerK. SauterK. EiberM. MaurerT. SchwaigerM. GschwendJ.E. CombsS.E. HablG. Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: A retrospective study.Radiat. Oncol.20161117310.1186/s13014‑016‑0646‑227229485
     [Google Scholar]
  28. GrubmüllerB. BaltzerP. D’AndreaD. KornS. HaugA.R. HackerM. GrubmüllerK.H. GoldnerG.M. WadsakW. PfaffS. BabichJ. SeitzC. FajkovicH. SusaniM. MazalP. KramerG. ShariatS.F. HartenbachM. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making.Eur. J. Nucl. Med. Mol. Imaging201845223524210.1007/s00259‑017‑3858‑229075832
     [Google Scholar]
/content/journals/cmir/10.2174/0115734056276494231207101146
Loading
Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer
Curr. Med. Imaging 20, e15734056276494 (2024); https://doi.org/10.2174/0115734056276494231207101146
/content/journals/cmir/10.2174/0115734056276494231207101146
/content/journals/cmir/10.2174/0115734056276494231207101146
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): 68Ga-PSMA; Impact; Management change; PET/CT; Prostate cancer; Survival

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test